ERC Consolidator Grant · 2025
Astrocytic Metabolic Reprogramming as a Therapeutic Target for Alzheimer’s Disease
Alzheimer's disease (AD) represents a growing public health challenge, with its prevalence steadily increasing profoundly affecting both patients and their families. Despite extensive research focusing on amyloid-beta and tau as central pathological hallmarks of AD, the crucial role of astrocytic metabolism in neurodegeneration has often been overlooked. The HyperAstroMet project introduces a novel approach by investigating astrocytic hypermetabolism as a pivotal driver of neuronal hyperexcitability, dysfunction, and cognitive decline in AD. Astrocytes, integral to brain energy homeostasis, undergo significant metabolic reprogramming in the context of AD, marked by excessive glycolysis,…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.